Immune Design Corp. (IMDZ) announced after the close Monday that it plans to initiate a Phase 3 trial for CMB305 based on discussions it held with the FDA. The stock is now up 0.90 on 4K shares.
Immune Design declined throughout the first half of Monday's session and closed down by 0.85 at $10.10. The stock fell to nearly a 3-week low.
For comments and feedback contact: editorial@rttnews.com
Business News